Answers are grounded in this paper and cite their sources.
Background & Aims: entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level. Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022. Multi-state modeling was applied to evaluate treatment impacts on disease progression trajectory, comprising CHB (with/without compensated cirrhosis), hepatic decompensation, HCC, death, and a switching treatment state. Propensity score matching/weighting and subgroup analyses were used to confirm the robustness of findings. Results: During a median 6.3 years of follow-up, 1,524 patients developed hepatic decompensation, 3,591 developed HCC, and 3,436 died. Tenofovir compared with entecavir was associated with lower risk of CHB progression, with adjusted-hazard ratios (95% CIs) of 0.84 (0.75-0.95) and 0.76 (0.70-0.83), respectively, for transitions to hepatic decompensation and HCC from baseline, and 0.65 (0.48-0.89) for HCC risk from decompensation. Propensity score matching/weighting analyses yielded similar results. Among patients without experiencing decompensation, a significantly lower HCC risk with tenofovir was observed across multiple subgroups, including age, sex, diabetes, and cirrhosis, and by sensitivity analyses. The 5-year risk of major adverse liver-related outcomes (decompensation, HCC, and liver-related deaths) was 5.5% and 7.5% for tenofovir and entecavir, respectively (adjusted-hazard ratio 0.80; 95% CI 0.74-0.85). Conclusions: Using multi-state modeling on the temporal evolution of CHB severity, long-term tenofovir treatment compared with entecavir was associated with a lower risk of severe liver outcomes. Impact and implications: entecavir) treatment is associated with lower risks of HCC, hepatic decompensation, and a composite endpoint of adverse liver-related outcomes (hepatic decompensation, HCC, and liver-related deaths), regardless of age, sex, diabetes, alcohol-related disorders, and cirrhosis state. Our results provide new evidence justifying the use of tenofovir or entecavir to prevent the evolution of CHB severity.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: